Castle Biosciences, Inc. (CSTL) Q4 2021 Earnings Results

Castle Biosciences, Inc. Beats on EPS, Stock Down 3.13%

Castle Biosciences reported a narrower loss than expected on EPS, which was a positive surprise for investors. However, the stock fell by 3.13% in response, indicating that investors may have had concerns about other aspects of the company's performance or future outlook, which were not detailed in the earnings call.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.25	N/A	+41.86%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Castle Biosciences, Inc. Beats on EPS, Stock Down 3.13%

Key numbers

Management commentary

Castle Biosciences, Inc.

More earnings this week

Castle Biosciences, Inc. Beats on EPS, Stock Down 3.13%

Key numbers

Management commentary